Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-Year Long Term Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials Including Laboratory Parameters

Deucravacitinib demonstrated a consistent safety profile over 5 years with more than 5,000 patient years of exposure, showing no increase in adverse events, serious adverse events, or the emergence of new safety signals. Rates of serious infections, malignancy, and MACE events remained low and were similar to those seen with approved psoriasis treatments in both clinical trials and real-world data. Additionally, no significant changes were observed from baseline chemistry or lipid parameters, and there were no signature changes in laboratory values associated with JAK1, JAK2, or JAK3 inhibitors, such as increased cholesterol, serum transaminases, or CPK levels.  Efficacy was sustained over 5 years in over 500 patients who were continuously treated from day 1 in the parent trials, with PASI 75, PASI 90, and sPGA 0/1 responses remaining stable. The results were consistent across different imputation methods, further supporting the reliability of the findings. These data confirm the long-term safety and durable efficacy of deucravacitinib, the first-in-class allosteric TYK2 inhibitor for psoriasis.

Click here for a link to the original posters

Elevate-Derm Alliance Editorial Board